DNA Damage Response in Cancer: Mechanisms, Implications, and Therapeutic Opportunities

Abstract

The DNA Damage Response (DDR) constitutes an intricate network of sensing, signaling, and repair pathways that safeguards genomic stability against a constant barrage of endogenous metabolic by-products and exogenous genotoxic insults. Upon lesion recognition, specialized sensor complexes—such as the MRN (MRE11–RAD50–NBS1) and KU70/80 assemblies—activate master transducer kinases ATM, ATR, and DNA-PKcs, which in turn orchestrate a multilayered cascade of post-translational modifications, cell-cycle checkpoints, chromatin remodeling, and transcriptional re-programming. Downstream effector modules channel the repair of single- and double-strand breaks through error-free (homologous recombination, nucleotide- and base-excision, mismatch repair) or error-prone (non-homologous end-joining, translesion synthesis) mechanisms, thereby balancing genomic fidelity with cellular viability. In oncogenesis, germline or somatic aberrations in DDR genes—exemplified by BRCA1/2, ATM, CHEK2, and mismatch-repair components—fuel genomic instability, clonal evolution, and therapeutic resistance. Paradoxically, these defects create synthetic-lethal vulnerabilities that can be therapeutically leveraged. The clinical success of PARP inhibitors in BRCA-mutant breast, ovarian, pancreatic, and prostate cancers has validated DDR targeting as a precision-oncology paradigm and catalyzed the development of next-generation agents against ATR, ATM, DNA-PK, CHK1/2, and WEE1. Combinatorial regimens coupling DDR inhibitors with immune checkpoint blockade, radiotherapy, and epigenetic modulators are broadening the therapeutic horizon, while circulating tumor DNA and functional genomic screens are refining patient stratification. This review synthesizes current insights into DDR molecular circuitry, delineates how DDR dysfunction shapes the mutational landscape and tumor microenvironment, and critically appraises emerging translational strategies. By integrating mechanistic biology with clinical evidence, we highlight opportunities and challenges in harnessing DDR pathways to improve cancer prognosis and overcome resistance, paving the way for next-generation, genotype-directed interventions.